Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Venlafaxine in Depressed Patients

Wyeth Pharmaceuticals (Canada)0 个研究点目标入组 40 人开始时间: 2005年9月29日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Male or female patients between 18 and 65 years of age
•2. Diagnosis of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatry Association, 1994) using the Structured Clinical Interview for Depression (SCID) (Spitzer 1992)
•3. Initial global score 18 on the 17-item Hamilton depression rating scale
•4. Written informed consent signed by the patient

•1. Evidence of significant physical illness contraindicating the use of Venlafaxine, Paroxetine or Atomoxetine found on physical or in the laboratory data obtained during the first week of the study
•2. Evidence of suicidality or severity of depression precluding safe participation in the study
•3. Mental retardation (IQ lower than 80) rendering the response to investigators unreliable
•4. Pregnancy, or absence of adequate contraceptive method in women with childbearing potential
•5. Concurrent use of psychotropic medication such as antipsychotics, mood stabilizers or regular use of high doses of benzodiazepines
•6. Lack of response or intolerance to optimal doses of Paroxetine, Venlafaxine or Atomoxetine
•7. Participation in another clinical trial within 30 days of entry into the current study

发起方

Wyeth Pharmaceuticals (Canada)